Compare · MRK vs NATR
MRK vs NATR
Side-by-side comparison of Merck & Company Inc. (MRK) and Nature's Sunshine Products Inc. (NATR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and NATR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $295.19B, about 849.5x NATR ($347.5M).
- Over the past year, MRK is up 50.7% and NATR is up 36.4% - MRK leads by 14.3 points.
- MRK has been more active in the news (27 items in the past 4 weeks vs 17 for NATR).
- MRK has more recent analyst coverage (25 ratings vs 5 for NATR).
- Company
- Merck & Company Inc.
- Nature's Sunshine Products Inc.
- Price
- -
- -
- Market cap
- $295.19B
- $347.5M
- 1M return
- +6.40%
- -18.86%
- 1Y return
- +50.70%
- +36.45%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 27
- 17
- Recent ratings
- 25
- 5
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Nature's Sunshine Products Inc.
Nature's Sunshine Products, Inc., a natural health and wellness company, primarily manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. It also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. The company offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is based in Lehi, Utah.
Latest MRK
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
- SEC Form 4 filed by Director Warden Kathy J
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- SEC Form 4 filed by Director Thulin Inge G
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Russo Patricia F
- SEC Form 4 filed by Director Rothman Paul
- SEC Form 4 filed by Director Mayo Stephen
Latest NATR
- EVP & President, Asia Norman Daniel C sold $200,476 worth of shares (9,713 units at $20.64), decreasing direct ownership by 17% to 47,276 units (SEC Form 4)
- EVP, General Counsel Brower Nathan G sold $262,408 worth of shares (12,015 units at $21.84), decreasing direct ownership by 22% to 43,438 units (SEC Form 4)
- Director Fasching Steven J. was granted 4,500 shares, increasing direct ownership by 41% to 15,369 units (SEC Form 4)
- Director Wissmiller Heidi was granted 4,500 shares, increasing direct ownership by 12% to 41,667 units (SEC Form 4)
- EVP & President, Europe Yates Bryant J was granted 8,753 shares, increasing direct ownership by 11% to 89,414 units (SEC Form 4)
- EVP, Global Supply Chain Fritz Erich A was granted 9,226 shares, increasing direct ownership by 79% to 20,889 units (SEC Form 4)
- Director May Katie was granted 4,500 shares, increasing direct ownership by 46% to 14,266 units (SEC Form 4)
- EVP, General Counsel Brower Nathan G was granted 9,001 shares, increasing direct ownership by 19% to 55,453 units (SEC Form 4)
- Chief Executive Officer Romanzi Kenneth G. was granted 33,753 shares, increasing direct ownership by 31% to 143,999 units (SEC Form 4)
- SVP, Chief Accounting Officer Lanoy Jonathan David was granted 6,107 shares, increasing direct ownership by 14% to 48,392 units (SEC Form 4)